Bile Duct Cancer Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Bile duct cancer encompasses cholangiocarcinoma and other biliary tract malignancies, a relatively rare cancer type with an estimated incidence of 1-2 cases per 100,000 people in the United States. The 2025 global market is valued at approximately $484 billion, expanding at an 8.87% CAGR as pharmaceutical, diagnostic, and device revenues tied to biliary cancer care scale up. Despite low individual incidence, the high unmet medical need and premium pricing of targeted therapies give the segment outsized commercial weight.

• •Global 2025 valuation: ~$484 billion, 8.87% CAGR
• •Rare disease: US incidence ~1-2 per 100,000 per SEER data
• •Rising revenues driven by premium-priced targeted therapies

Growth is primarily powered by the shift toward biomarker-driven systemic therapy, expanded genomic profiling, and faster regulatory approvals for novel agents in biliary tract cancer. Aging populations, improved diagnostic imaging, and earlier detection through surveillance programs also widen the addressable patient pool. Rising R&D investment from large pharmaceutical players and biotechs continues to expand the late-stage clinical pipeline.

• •Biomarker-driven targeted therapy adoption
• •Aging populations and improved detection rates
• •Accelerated regulatory pathways for novel BTC agents

The market segments by therapy type (chemotherapy, targeted therapy, immunotherapy), line of treatment, and end-user setting, with targeted therapies capturing the fastest-growing share. North America leads revenue contribution owing to high healthcare spending, established precision-oncology infrastructure, and earlier adoption of new agents; Asia-Pacific is the fastest-growing region as China, Japan, and South Korea expand oncology access and launch domestic BTC programs.

• •By therapy: targeted and immunotherapy segments growing fastest
• •North America holds the largest revenue share
• •Asia-Pacific is the fastest-growing regional market

What are the recent trends and outlook?

The pipeline is increasingly shaped by combination regimens that pair targeted therapies with immune checkpoint inhibitors, alongside next-generation sequencing becoming standard at diagnosis. ADC and cyclic peptide platforms are attracting significant investment for biliary indications, supporting a robust outlook through the end of the decade. With the market compounding at roughly 8.87% annually, revenues tied to BTC therapeutics, diagnostics, and supportive care are expected to continue outpacing broader oncology growth.

• •Targeted-plus-immunotherapy combinations entering late-stage trials
• •NGS-based profiling becoming standard of care
• •Market projected to outpace broader oncology growth through 2030